转移性激素敏感型前列腺癌的系统性三联疗法。
SYSTEMIC TRIPLE THERAPY IN METASTATIC HORMONE SENSITIVE PROSTATE CANCER (MHSPC).
机构信息
Department of Oncology and Radiotherapy, University Hospital Split, School of Medicine, University of Split.
出版信息
Acta Clin Croat. 2022 Oct;61(Suppl 3):81-85. doi: 10.20471/acc.2022.61.s3.12.
Abstract
For many years, androgen deprivation therapy (ADT) as monotherapy has been the gold standard for metastatic hormone-sensitive prostate cancer (mHSPC) treatment. Several studies have been published within the last decade demonstrating a significant survival advantage resulting from combining the treatment with standard ADT plus docetaxel or androgen receptor targeted therapy (ARTA) compared to ADT monotherapy. Recently published data of the PEACE-1 and ARASENS trials suggest that in the future, triple therapy might be a treatment option for patients with mHSPC.
摘要
多年来，雄激素剥夺疗法（ADT）单药治疗一直是转移性激素敏感前列腺癌（mHSPC）治疗的金标准。过去十年中发表的多项研究表明，与 ADT 单药治疗相比，联合标准 ADT 加多西他赛或雄激素受体靶向治疗（ARTA）治疗可显著提高生存率。最近发表的 PEACE-1 和 ARASENS 试验数据表明，未来，三联疗法可能是 mHSPC 患者的一种治疗选择。
相似文献
1
SYSTEMIC TRIPLE THERAPY IN METASTATIC HORMONE SENSITIVE PROSTATE CANCER (MHSPC).转移性激素敏感型前列腺癌的系统性三联疗法。
Acta Clin Croat. 2022 Oct;61(Suppl 3):81-85. doi: 10.20471/acc.2022.61.s3.12.
2
[Androgen deprivation therapy plus chemotherapy ± androgen receptor-targeting agents for metastatic hormone-sensitive prostate cancer].雄激素剥夺疗法联合化疗±雄激素受体靶向药物治疗转移性激素敏感性前列腺癌
Urologie. 2023 Apr;62(4):360-368. doi: 10.1007/s00120-023-02029-0. Epub 2023 Feb 10.
3
Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer: Updated Network Meta-analysis Stratified by Disease Volume.三药联合或两药联合治疗转移性激素敏感型前列腺癌：按疾病负荷分层的更新网络荟萃分析。
Eur Urol Focus. 2023 Sep;9(5):838-842. doi: 10.1016/j.euf.2023.03.024. Epub 2023 Apr 11.
4
Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients: A Systematic Review and Network Meta-analysis.三药联合或两药联合治疗转移性激素敏感型前列腺癌患者：系统评价和网络荟萃分析。
Eur Urol Focus. 2023 Jan;9(1):96-105. doi: 10.1016/j.euf.2022.08.007. Epub 2022 Sep 1.
5
Addition of New Androgen Receptor Pathway Inhibitors to Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review and Metanalysis.多西他赛联合雄激素剥夺治疗联合新型雄激素受体通路抑制剂治疗转移性激素敏感性前列腺癌的系统评价和荟萃分析。
Curr Oncol. 2022 Dec 4;29(12):9511-9524. doi: 10.3390/curroncol29120747.
6
Chemotherapy and advanced androgen blockage, alone or combined, for metastatic hormone-sensitive prostate cancer a systematic review and meta-analysis.化疗和雄激素阻断单独或联合用于转移性激素敏感前列腺癌的系统评价和荟萃分析。
Cancer Treat Rev. 2022 Nov;110:102441. doi: 10.1016/j.ctrv.2022.102441. Epub 2022 Jul 26.
7
Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a patient and caregiver perspective and plain language summary of the ARASENS trial.达罗他胺与转移性、激素敏感性前列腺癌的生存：一项 ARASENS 试验的患者和护理人员视角以及通俗易懂的总结。
Future Oncol. 2022 Jul;18(21):2585-2597. doi: 10.2217/fon-2022-0433. Epub 2022 Jun 3.
8
Addition of Docetaxel to Androgen Receptor Axis-targeted Therapy and Androgen Deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis.多西他赛联合雄激素受体轴靶向治疗和雄激素剥夺治疗在转移性激素敏感前列腺癌中的应用：一项网状荟萃分析。
Eur Urol Oncol. 2022 Oct;5(5):494-502. doi: 10.1016/j.euo.2022.06.003. Epub 2022 Jul 8.
9
Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate Cancer.达罗他胺：用于治疗转移性去势敏感性前列腺癌的药物。
Target Oncol. 2023 Sep;18(5):793-800. doi: 10.1007/s11523-023-00984-4. Epub 2023 Aug 5.
10
[New treatment approaches for and ongoing trials in metastatic hormone-sensitive prostate cancer].转移性激素敏感性前列腺癌的新治疗方法及正在进行的试验
Urologie. 2023 Apr;62(4):369-375. doi: 10.1007/s00120-023-02046-z. Epub 2023 Feb 23.
引用本文的文献
1
Precise prediction of bone metastases and metastatic burden using exosomal mirnas and radiomics: a multi-center study.利用外泌体微小RNA和放射组学精确预测骨转移及转移负荷：一项多中心研究
J Transl Med. 2025 Jun 18;23(1):677. doi: 10.1186/s12967-025-06691-0.
2
Plasma Cell-Free DNA Methylation-Based Prognosis in Metastatic Castrate-Resistant Prostate Cancer.基于游离血浆DNA甲基化的转移性去势抵抗性前列腺癌预后研究
Res Sq. 2025 Apr 21:rs.3.rs-6331572. doi: 10.21203/rs.3.rs-6331572/v1.
3
Circulatory prostate cancer proteome landscapes and prognostic biomarkers in metastatic castrate resistant prostate cancer.转移性去势抵抗性前列腺癌的循环前列腺癌蛋白质组图谱及预后生物标志物
Clin Proteomics. 2025 Apr 18;22(1):13. doi: 10.1186/s12014-025-09536-6.
本文引用的文献
1
Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer.达罗他胺与转移性去势敏感性前列腺癌的生存
**注**：这是基于你提供的文本进行的翻译，实际翻译可能会因上下文和语言习惯而有所不同。
N Engl J Med. 2022 Mar 24;386(12):1132-1142. doi: 10.1056/NEJMoa2119115. Epub 2022 Feb 17.
2
Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study.阿帕鲁胺治疗转移性去势敏感性前列腺癌患者的生存分析：随机、双盲、III 期 TITAN 研究的最终生存分析。
J Clin Oncol. 2021 Jul 10;39(20):2294-2303. doi: 10.1200/JCO.20.03488. Epub 2021 Apr 29.
3
Metastatic Hormone-Sensitive Prostate Cancer: A Review of the Current Treatment Landscape.转移性激素敏感型前列腺癌：当前治疗格局的综述。
Cancer J. 2020 Jan/Feb;26(1):64-75. doi: 10.1097/PPO.0000000000000418.
4
ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer.ARCHES：雄激素剥夺治疗联合恩扎卢胺或安慰剂治疗转移性去势敏感性前列腺癌的随机 III 期研究。
J Clin Oncol. 2019 Nov 10;37(32):2974-2986. doi: 10.1200/JCO.19.00799. Epub 2019 Jul 22.
5
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.恩扎卢胺联合标准一线治疗转移性前列腺癌。
N Engl J Med. 2019 Jul 11;381(2):121-131. doi: 10.1056/NEJMoa1903835. Epub 2019 Jun 2.
6
Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.阿帕鲁胺治疗转移性去势敏感性前列腺癌。
N Engl J Med. 2019 Jul 4;381(1):13-24. doi: 10.1056/NEJMoa1903307. Epub 2019 May 31.
7
Characterization of Differences Between Prostate Cancer Patients Presenting With De Novo Versus Primary Progressive Metastatic Disease.初发性与原发性进行性转移性疾病的前列腺癌患者之间差异的特征分析
Clin Genitourin Cancer. 2017 Aug 31. doi: 10.1016/j.clgc.2017.08.006.
8
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.阿比特龙联合泼尼松治疗转移性去势敏感性前列腺癌。
N Engl J Med. 2017 Jul 27;377(4):352-360. doi: 10.1056/NEJMoa1704174. Epub 2017 Jun 4.
9
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.转移性激素敏感性前列腺癌的化学激素疗法
N Engl J Med. 2015 Aug 20;373(8):737-46. doi: 10.1056/NEJMoa1503747. Epub 2015 Aug 5.
10
Who dies from prostate cancer?谁死于前列腺癌？
Prostate Cancer Prostatic Dis. 2014 Dec;17(4):348-52. doi: 10.1038/pcan.2014.35. Epub 2014 Oct 14.
Zotero 插件